Characteristics of Zika virus infection among international travelers: A prospective study from a Spanish referral unit

Crespillo-Andújar, Clara; Díaz‐Menéndez, Marta; Trigo, Elena; Arsuaga, Marta; Calle, Fernando; Lago, Mar; Guevara, M C Ladrón de; Barreiro, Pablo; Montero, Dolores; García‐Bujalance, Silvia; Alvarado, Eugenia Antolín; Calle, María de la; Sánchez-Seco, María Paz; Ory, Fernando de; Vázquez, Ana; Arribas, José Ramón; Bobes, Julio; Martín-Boado, Elena; Martínez-Sánchez, Nuria; Rodríguez, Roberto; Herrero, Beatriz; López, Francisco Pérez; Bartha, José Luis; Elorza, M D; Lafuente, Marta Cabrera; Hortelano, M. García López

doi:10.1016/j.tmaid.2019.101543

Cited by 6 publications

(6 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Since 2018, the ZIKV epidemic has waned, presumably due to immunity from the last outbreak, making it almost impossible to conduct clinical end-point efficacy trials. However, sporadic ZIKV transmission continues, and poses a potential health threat to travelers 20 , 21 with the potential for future regional epidemics.…”

Section: Introductionmentioning

confidence: 99%

Protective efficacy of a Zika purified inactivated virus vaccine candidate during pregnancy in marmosets

Kim,

Gonzalez,

Tighe

et al. 2024

npj Vaccines

View full text Add to dashboard Cite

Zika virus (ZIKV) infection during pregnancy poses significant threats to maternal and fetal health, leading to intrauterine fetal demise and severe developmental malformations that constitute congenital Zika syndrome (CZS). As such, the development of a safe and effective ZIKV vaccine is a critical public health priority. However, the safety and efficacy of such a vaccine during pregnancy remain uncertain. Historically, the conduct of clinical trials in pregnant women has been challenging. Therefore, clinically relevant animal pregnancy models are in high demand for testing vaccine efficacy. We previously reported that a marmoset pregnancy model of ZIKV infection consistently demonstrated vertical transmission from mother to fetus during pregnancy. Using this marmoset model, we also showed that vertical transmission could be prevented by pre-pregnancy vaccination with Zika purified inactivated virus (ZPIV) vaccine. Here, we further examined the efficacy of ZPIV vaccination during pregnancy. Vaccination during pregnancy elicited virus neutralizing antibody responses that were comparable to those elicited by pre-pregnancy vaccination. Vaccination also reduced placental pathology, viral burden and vertical transmission of ZIKV during pregnancy, without causing adverse effects. These results provide key insights into the safety and efficacy of ZPIV vaccination during pregnancy and demonstrate positive effects of vaccination on the reduction of ZIKV infection, an important advance in preparedness for future ZIKV outbreaks.

show abstract

Section: Introductionmentioning

confidence: 99%

Protective efficacy of a Zika purified inactivated virus vaccine candidate during pregnancy in marmosets

Kim,

Gonzalez,

Tighe

et al. 2024

npj Vaccines

View full text Add to dashboard Cite

show abstract

“…Since 2018, the ZIKV epidemic has waned, presumably due to immunity from the last outbreak, making it almost impossible to conduct clinical end-point e cacy trials. However, sporadic ZIKV transmission continues, and poses a potential health threat to travelers 20,21 with the potential for future regional epidemics. WHO's Zika virus Research and Development Roadmap has targeted the development of products for women of child bearing potential for emergency use in the next outbreak, rather than for preventive use 22 .…”

Section: Introductionmentioning

confidence: 99%

Protective efficacy of a Zika purified inactivated virus vaccine candidate during pregnancy in marmosets

Kim,

Gonzalez,

Tighe

et al. 2023

Preprint

View full text Add to dashboard Cite

Zika virus (ZIKV) infection during pregnancy poses significant threats to maternal and fetal health, leading to intrauterine fetal demise and severe developmental malformations that constitute congenital Zika syndrome (CZS). As such, the development of a safe and effective ZIKV vaccine is a critical public health priority. However, the safety and efficacy of such a vaccine during pregnancy remain uncertain. Historically, the conduct of clinical trials in pregnant women has been challenging. Therefore, clinically relevant animal pregnancy models are in high demand for testing vaccine efficacy. We previously reported that a marmoset pregnancy model of ZIKV infection consistently demonstrated vertical transmission from mother to fetus during pregnancy. Using this marmoset model, we also showed that vertical transmission could be prevented by pre-pregnancy vaccination with Zika purified inactivated virus (ZPIV) vaccine. Here, we further examined the efficacy of ZPIV vaccination during pregnancy. Vaccination during pregnancy elicited virus neutralizing antibody responses that were comparable to those elicited by pre-pregnancy vaccination. Vaccination also prevented vertical transmission of ZIKV during pregnancy, without causing adverse effects. These results provide key insights into the safety and protective efficacy of ZPIV vaccination during pregnancy, an important advance in preparedness for future ZIKV outbreaks.

show abstract

“…El diagnóstico de ZIKV sigue siendo un desafío debido a las reacciones cruzadas serológicas y la similitud clínica de la infección por ZIKV con otros flavivirus. Este hecho, junto con el acceso limitado a las pruebas de diagnóstico en países endémicos, ha llevado a un diagnóstico insuficiente en muchos casos, lo que dificulta la estimación del riesgo real de infección tanto para la población endémica como para los viajeros (6). Se vuelve crítico identificar a aquellos viajeros con riesgo de introducción potencial de la enfermedad a nuevas áreas, para prevenir brotes o circulación endémica del virus (6).…”

Section: Introductionunclassified

Infección por virus de Zika

Quirós¹,

Molina²

2020

Rev.méd.sinerg.

View full text Add to dashboard Cite

El Zika es un flavivirus transmitido principalmente por la picadura de mosquitos infectados. Los signos y síntomas pueden incluir erupción cutánea, prurito, fiebre, dolor de cabeza, artralgia, mialgia, conjuntivitis, dolor lumbar y dolor retro orbitario. Se trata de un virus teratógeno, el cual puede provocar microcefalia, entre otras malformaciones congénitas; además se asocia a síndrome de Guillain Barré en adultos. Debido al riesgo de transmisión intrauterina, es importante realizar ecografías seriadas a las gestantes para controlar el crecimiento fetal y la neuroanatomía. Su diagnóstico se realiza pediante sospecha clínica y se confirma con pruebas de amplificación de ácidos nucleicos y pruebas de anticuerpos IgM. Eliminar los lugares donde el mosquito pone huevos, principalmente contenedores artificiales que contienen agua además del uso de repelentes tópicos contra insectos, es de vital importancia como medidas de prevención. El tratamiento es sintomático, mediante medidas de soporte como hidratación, analgesia y antihistamínicos.

show abstract

Characteristics of Zika virus infection among international travelers: A prospective study from a Spanish referral unit

Cited by 6 publications

References 36 publications

Protective efficacy of a Zika purified inactivated virus vaccine candidate during pregnancy in marmosets

Protective efficacy of a Zika purified inactivated virus vaccine candidate during pregnancy in marmosets

Protective efficacy of a Zika purified inactivated virus vaccine candidate during pregnancy in marmosets

Infección por virus de Zika

Contact Info

Product

Resources

About